Evaluation of COX-2 Expression in Renal Cell Carcinoma and its correlation with clinicopathological factors: A tissue microarray study.

Guheina Abdullah Ashour, Warda M. Said


Objectives: this study, aimed to evaluate the expression of COX2 in renal cell carcinoma (RCC), and correlate it with different patient clinicopathological data, emphasizing on the role of COX2 as a prognostic factor for RCC and to decide which cases more likely  benefit from the targeted therapy later on.

Patients and Methods: the present series consisted of tissue samples obtained from 50 patients (30 patients were men and 20 were women). All the tumor samples were collected from the Pathology Department, Faculty of Medicine, Alexandria University during the period from July 2009 to November 2010.  Archival paraffin-embedded RCC tissue samples were used to prepare tissue microarray blocks for immunohistochemical staining with COX2 antibody. Marker expression was categorized for statistical analysis then correlated to clinicopathological variables.

Results: the histological types was significantly associated with COX2 expression, with higher expression being more common in  papillary RCC and chromophobe RCC, the majority of these two types were in score 1 and 2  while majority of  clear cell RCC had  score 0 and 1 (P=0.011*).

Conclusion: The association of COX-2 marker was related to the histologic type of tumor; COX2 expression study might provide prognostic information regarding tumor aggressiveness. These findings suggested a potential impact of COX2 targeted therapy in the treatment of RCC with overexpressed COX2 that needs further investigation.

Full Text:



Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB. Celecoxib for the prevention of colorectal adenomatous polyps. New England Journal of Medicine. 2006;355(9):885-95.

Chen Q, Shinohara N, Abe T, Harabayashi T, Nonomura K. Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. The Journal of urology. 2004;172(6):2153-7.

Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS, Ng HT, Yuan CC. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecologic oncology. 2003;88(3):379-85.

Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB, Kim SJ. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei medical journal. 2005;46(1):133-40.

Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB, Kim SJ. Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei medical journal. 2005;46(1):133-40.

Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S. Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97(12):2978-87.

Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology. 1982;6(7):655-64.

Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. American Journal of Physiology-Renal Physiology. 2001;281(1):F1-1.

GÜÇER H, ŞAHAN E, İĞDEM AA, TETİKKURT ÜS, ERDOĞAN N. Cox-2 Expression and Microvessel Density in Clear Cell Type Renal Cell Carcinoma. Turkish Journal of Pathology.;25(2):013-9.

Hashimoto Y, Kondo Y, Kimura G, Matsuzawa I, Sato S, Ishizaki M, Imura N, Akimoto M, Hara S. Cyclooxygenase‐2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology. 2004;44(4):353-9.

Erdem H, Aydin HR, Bahadir A, Gündogdu B, Balta H, Sener E, Kayikci MA, Albayrak A, Erdogan F. Relationship of CD95 and COX-2 in renal cell carcinomas with survival and other prognostic parameters: A tissue microarray study. apoptosis. 2015;8:9.

Hida T, Kozaki KI, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, Sugiura T, Ogawa M, Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clinical Cancer Research. 2000;6(5):2006-11.

Joo YE, Rew JS, Seo YH, Choi SK, Kim YJ, Park CS, Kim SJ. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. Journal of clinical gastroenterology. 2003;37(1):28-33.

Kankuri-Tammilehto MK, SÖDERSTRÖM KO, Pelliniemi TT, Vahlberg T, PYRHÖNEN SO, Salminen EK. Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer research. 2010;30(7):3023-30.

Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research. 2001;7(4):861-7.

Kononen J, Bubendorf L, Kallionimeni A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature medicine. 1998;4(7):844-7.

Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H. The Heidelberg classification of renal cell tumours. The Journal of pathology. 1997;183(2):131-3.

Lee JW, Park JH, Suh JH, Nam KH, Choe JY, Jung HY, Chae JY, Moon KC. Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean journal of pathology. 2012;46(3):237.

Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS. Guidelines on renal cell carcinoma. European association of urology. 2013:28.

Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clinical Cancer Research. 2000;6(10):4064-8.

Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma. Clinical cancer research. 2003;9(5):1741-9.

Mungan MU, Gurel D, Canda AE, Tuna B, Yorukoglu K, Kirkali Z. Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma. European urology. 2006;50(1):92-7.

Rosai J. Rosai and Ackerman's Surgical Pathology E-Book. Elsevier Health Sciences; 2011 Jun 20.

Yang S, Gao Q, Jiang W. Relationship between tumour angiogenesis and expression of cyclo-oxygenase-2 and vascular endothelial growth factor-A in human renal cell carcinoma. Journal of International Medical Research. 2015;43(1):110-7.

Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clinical Cancer Research. 2000;6(6):2424-30.

Sinicrope FA, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer research. 1995;55(2):237-41.

Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. UICC International Union against cancer. 7th ed. Weinheim, Germany: Wiley-Blackwell; 2009. pp. 255–257.

Sun H, Wang H, Qin WJ, Yang B, Wang SC, Jian BL. Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi bao yu fen zi mian yi xue za zhi= Chinese journal of cellular and molecular immunology. 2009;25(4):348-50.

Tabriz HM, Mirzaalizadeh M, Gooran S, Niki F, Jabri M. COX-2 expression in renal cell carcinoma and correlations with tumor grade, stage and patient prognosis. Asian Pacific Journal of Cancer Prevention. 2016;17(2):535-8.

Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z. Significance of COX-2 expression in human renal cell carcinoma. Urology. 2004;64(6):1116-20.

Wang X, Zhang L, O'neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG, Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. British journal of cancer. 2013;108(2):319-26.

Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase‐2 in prostate carcinoma. Cancer. 2000;89(3):589-96.

Zhang Y, Dong S, Xu R, Yang Y, Zheng Z, Wang X, Ren R, Sun R, Li M, Yang H, Huang Y. Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy. Oncology Letters. 2017;13(4):2549-56.

Zhou TJ, Zhang SL, He CY, Zhuang QY, Han PY, Jiang SW, Yao H, Huang YJ, Ling WH, Lin YC, Lin ZN. Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1. Theranostics. 2017;7(5):1389.


  • There are currently no refbacks.